Showing Results for: “diabetes”

The American Diabetes Association® (ADA) and Obesity Action Coalition (OAC) today celebrated the progress made in the Texas House of Representatives this session in advancing understanding about the need to address obesity and its impact on the long-term health of the state. House Bill 2677, sponsored by Rep. Senfronia Thompson and co-sponsored by Rep. John Bucy III, would have provided Medicaid coverage for comprehensive treatment for people with obesity. Though HB 2677 cleared the House Public Health Committee with bipartisan support and no registered opposition and was scheduled for a vote

The American Diabetes Association ® (ADA) is thrilled to announce the recipients of the 2023 National Scientific and Health Care Achievement Awards. The awards honor academics, health care providers, and educators who have contributed to substantial advances in the field of diabetes care and research. With the help of these leaders and their steadfast dedication, we move closer to achieving the mission of the ADA: To prevent and cure diabetes and to improve the lives of all people affected by diabetes. “The ADA’s National Scientific and Health Care Achievement Awards honor those who have made

Leading diabetes researchers and clinicians from around the world highlight impact of pandemic on patient outcomes and key learnings The American Diabetes Association ® (ADA) is kicking off the virtual 81st Scientific Sessions tomorrow and will feature five COVID-19 Symposia, highlighting cutting-edge science and the latest diabetes developments learned during the initial phases of the pandemic. The Symposia will be presented over the course of the annual meeting taking place June 25–29. This latest research comes at a time when individuals with diabetes, and other related underlying health

Following the release of President Trump’s budget proposal for Fiscal Year 2021, Tracey D. Brown, Chief Executive Officer of the American Diabetes Association (ADA), issued the following statement: “Yesterday, the White House announced its FY2021 budget. While we were encouraged to see that the President recommended extending the highly successful Special Diabetes Program (SDP), we ask Congress to go further and provide a long-term renewal for SDP. In addition, far too many other public health and biomedical research programs would be subject to severe cuts under the President’s proposal

Millions of Americans will lose access to safety net programs that provide critical access to care, medications, diabetes technology, and food for people with diabetes The American Diabetes Association® (ADA), issued the following statement in response to the U.S. House of Representative’s approval of H.R. 1, the reconciliation bill that significantly cuts access to health care and nutrition programs for millions of Americans living with diabetes. “The ADA is saddened and concerned by today’s action by the U.S. House of Representatives to approve the Senate version of H.R.1. The bill will

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use A new study evaluating the role of acmopatide (CT-868), a once-daily dual glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonist (GLP-1/GIP RA) injection, found that treatment improved blood glucose management, reduced body weight, and was generally well tolerated in patients with type 1 diabetes. The phase 2 trial results were presented today as a symposium at the 2026 Scientific Sessions of the American Diabetes Association ® in New Orleans. Approximately 1.2 million

American Diabetes Association Symposium Showcases New Potential Solution for Patients at High-Risk of Kidney Outcomes Today, findings from the landmark FLOW trial, the first dedicated kidney outcomes trial with a GLP-1 (glucagon-like peptide-1) receptor agonist were reported, demonstrating semaglutide significantly reduces the risk of major kidney disease events and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease. New data presented here also highlighted the likely benefits of combined therapy with SGLT2 inhibitors. The results were presented at a symposium

Today, the American Diabetes Association ® (ADA) in collaboration with the American Academy of Ophthalmology, the American Optometric Association, the American Society of Retinal Specialists, and the National Eye Institute, announced a new resource to improve communication between diabetes care clinicians and eye health clinicians. According to the Centers for Disease Control and Prevention (CDC), more than half of all people with diabetes don’t receive an annual dilated and comprehensive eye exam as recommended or are diagnosed with diabetes-related eye problems too late for effective

Update on SCORED and SOLOIST trials shows reduction in cardiovascular events and stroke using glucose-lowering agents Results from two large clinical trials show significant and early benefits from sotagliflozin, a drug that inhibits sodium-glucose transport protein 2 (SGLT2) and sodium-glucose transport protein 1 (SGLT1) in reducing heart failure, heart attack, and stroke—major problems in people with diabetes. The findings were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Patients with diabetes are at an increased risk of life-threatening

Findings Highlight Potential for Novel Approach to Insulin Delivery in Pediatric Population Today, a new study demonstrates inhaled insulin as a safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes. Results from the INHALE-1 study were presented today as a symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago. In the U.S., 304,000 children and adolescents have type 1 diabetes and depend on ongoing insulin treatment to regulate their blood glucose levels. Although most manage their condition through daily